Remove FDA Approval Remove Gene Remove Genomics Remove In-Vitro
article thumbnail

Can vertical AI advance cell and gene therapies? 

Drug Discovery World

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. General AI tools such as ChatGPT have acted as a catalyst, igniting a wave of AI innovation akin to the early days of the internet era.

article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

These tumor-derived entities are used to derive genomic and proteomic data. Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. In addition, liquid biopsy is a minimally invasive technology and has a much lower risk compared to tissue biopsy procedures.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

The Pharma Data

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

article thumbnail

Illumina debuts its multi-gene test for cancer in Europe

pharmaphorum

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. “Comprehensive genomic profiling has proven to be this platform.”

Gene 52
article thumbnail

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

Related: FDA Approves Rukobia for HIV Patients with Limited Treatment Options. This may help explain why HIV is adequately controlled, but not eradicated, with current treatments. The research study was published in Cell Reports.

RNA 52
article thumbnail

Can liquid biopsies transform precision medicine?

Drug Discovery World

CTCs reflect high levels of tumour heterogeneity, represent clonal evolution, and are suitable for treatment selection, real-time longitudinal disease monitoring and in vitro/in vivo culture. Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer.